|
MechanismBacterial DNA gyrase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date14 Sep 1993 |
|
Mechanismfungal CYP51A1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date01 Jan 1986 |
/ RecruitingNot Applicable 复方奥美拉唑干混悬剂健康受试者人体药代动力学和生物等效性试验
[Translation] Pharmacokinetics and bioequivalence study of compound omeprazole dry suspension in healthy volunteers
对湖南中威制药有限公司研制的复方奥美拉唑干混悬剂进行健康受试者人体药代动力学和生物等效性试验研究。通过研究健康受试者单剂量及持续给予复方奥美拉唑干混悬剂后的血药浓度经时过程,估算相应的药代动力学参数,旨为临床用药提供依据,并为该药的注册审批提供参考。
[Translation] The pharmacokinetics and bioequivalence test of compound omeprazole dry suspension in healthy subjects was conducted on the compound omeprazole dry suspension developed by Hunan Zhongwei Pharmaceutical Co., Ltd. The corresponding pharmacokinetic parameters were estimated by studying the time course of blood drug concentration after single dose and continuous administration of compound omeprazole dry suspension in healthy subjects, aiming to provide a basis for clinical medication and a reference for the registration and approval of the drug.
以奥美拉唑镁肠溶片为对照评价复方奥美拉唑干混悬剂治疗十二指肠溃疡安全性和有效性的临床研究
[Translation] Clinical study on the safety and efficacy of compound omeprazole dry suspension in the treatment of duodenal ulcer using omeprazole magnesium enteric-coated tablets as a control
评价复方奥美拉唑干混悬剂治疗活动性十二指肠溃疡的安全性和有效性
[Translation] To evaluate the safety and efficacy of compound omeprazole dry suspension in the treatment of active duodenal ulcer
100 Clinical Results associated with Hunan Zhongwei Pharmaceutical Co. Ltd.
0 Patents (Medical) associated with Hunan Zhongwei Pharmaceutical Co. Ltd.
100 Deals associated with Hunan Zhongwei Pharmaceutical Co. Ltd.
100 Translational Medicine associated with Hunan Zhongwei Pharmaceutical Co. Ltd.